This past summer, I reviewed Synopsys's (Nasdaq: SNPS) third-quarter earnings report and pronounced the stock "cheap." Well, three-and-a-half months and one earnings report later, the stock's 20% cheaper (even after last week's double-digit gains). But here's the bad news: Cheaper ain't the same as "cheap."
The year past
Synopsys reported its Q4 and full-year numbers last week. Most major news outlets are focusing on the short-term, Q4-only story. But seeing as this was a (fiscal) year-end report, let's be Foolish and look at the big picture, why don't we? Here's how fiscal 2009 turned out for Synopsys:
- Sales ended the year up 10% at $1.3 billion (helped by a 12% sprint in the final quarter).
- Profits leapt 48% to top out at $1.29 per share, once again with strong Q4 performance (18% growth) giving the year-end tally a boost.
These days, gloom prevails within Synopsys' customer base – chip makers like Intel (Nasdaq: INTC) and Actions Semiconductor (Nasdaq: ACTS), National Semiconductor (NYSE: NSM) and PMC-Sierra (Nasdaq: PMCS). The competition, too, is in disarray. Cadence Design (Nasdaq: CDNS) recently tried to grab Mentor Graphics (Nasdaq: MENT), but let slip its CEO instead.
In contrast, Synopsys seems confident it can thrive in the upcoming year. Fiscal 2009 guidance calls for roughly 8% sales growth to the $1.4 billion range (although earnings are expected to moderate, settling down about 10% at $1.16 or thereabouts).
The problem, future
More significant, though, to this Fool's ear, is the warning that cash from operations may be drying up. Whereas Synopsys generated in excess of $430 million in cash flow in fiscal 2007, and more than $330 million in the just-ended fiscal 2008, fiscal 2009 appears destined to produce just $210 million or so -- less than half last year's high-water mark.
Granted, capital expenditures are falling, too -- but not nearly as fast. Assuming the coming year sees a bit less capital spending than the year past, we're looking at cash profits of only about $170 million in 2009, or about what management expects for net income.
The present valuation
What this means, valuation-wise, is that Synopsys no longer looks as cheap as it did just three months ago. From a P/E perspective, the multiple of 14 seems rich relative to long-term growth expectations of 9%. Viewed from another angle, Synopsys sells for a forward enterprise value-to-free cash flow ratio of about 9 -- which looks like a fair price, but only just so.
Foolish takeaway
Much as I like the company, I wouldn't want to own it at today's price. Not, at least, until management finds a way to get its cash flow growing again. The present trend gives me chills.
For more on Synopsys, read:
Follow along with the Global Gains team as they travel to key business centers in China to uncover the very best investing opportunities! Sign up here to receive their FREE dispatches from the road.